GILD Quote, Financials, Valuation and Earnings

Biogen has a net margin of 19.72% compared to Gilead Sciences's net margin of 10.87%. Gilead Sciences's return on equity of 32.29% beat Biogen's return on equity of 10.33%.

Gilead Sciences has a consensus price target of $113.75, signalling upside risk potential of 10.26%. On the other hand Biogen has an analysts' consensus of $190.50 which suggests that it could grow by 60.3%. Given that Biogen has higher upside potential than Gilead Sciences, analysts believe Biogen is more attractive than Gilead Sciences.

Gilead Sciences has a beta of 0.322, which suggesting that the stock is 67.831% less volatile than S&P 500. In comparison Biogen has a beta of 0.057, suggesting its less volatile than the S&P 500 by 94.303%.

Gilead Sciences has a quarterly dividend of $0.79 per share corresponding to a yield of 3.01%. Biogen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Gilead Sciences pays 816.25% of its earnings as a dividend. Biogen pays out -- of its earnings as a dividend.

Gilead Sciences quarterly revenues are $6.7B, which are larger than Biogen quarterly revenues of $2.5B. Gilead Sciences's net income of $1.3B is higher than Biogen's net income of $266.7M. Notably, Gilead Sciences's price-to-earnings ratio is 21.72x while Biogen's PE ratio is 10.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Gilead Sciences is 4.53x versus 1.79x for Biogen. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of 19.72% compared to Gilead Sciences's net margin of 50.24%. Gilead Sciences's return on equity of 32.29% beat Johnson & Johnson's return on equity of 30.18%.

Gilead Sciences has a consensus price target of $113.75, signalling upside risk potential of 10.26%. On the other hand Johnson & Johnson has an analysts' consensus of $169.84 which suggests that it could grow by 9.87%. Given that Gilead Sciences has higher upside potential than Johnson & Johnson, analysts believe Gilead Sciences is more attractive than Johnson & Johnson.

Gilead Sciences has a beta of 0.322, which suggesting that the stock is 67.831% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.490, suggesting its less volatile than the S&P 500 by 50.995%.

Gilead Sciences has a quarterly dividend of $0.79 per share corresponding to a yield of 3.01%. Johnson & Johnson offers a yield of 3.21% to investors and pays a quarterly dividend of $1.24 per share. Gilead Sciences pays 816.25% of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Gilead Sciences's is not.

Gilead Sciences quarterly revenues are $6.7B, which are smaller than Johnson & Johnson quarterly revenues of $21.9B. Gilead Sciences's net income of $1.3B is lower than Johnson & Johnson's net income of $11B. Notably, Gilead Sciences's price-to-earnings ratio is 21.72x while Johnson & Johnson's PE ratio is 17.19x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Gilead Sciences is 4.53x versus 4.20x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 19.72% compared to Gilead Sciences's net margin of -117.16%. Gilead Sciences's return on equity of 32.29% beat Moderna's return on equity of -29.09%.

Gilead Sciences has a consensus price target of $113.75, signalling upside risk potential of 10.26%. On the other hand Moderna has an analysts' consensus of $49.96 which suggests that it could grow by 83.55%. Given that Moderna has higher upside potential than Gilead Sciences, analysts believe Moderna is more attractive than Gilead Sciences.

Gilead Sciences has a beta of 0.322, which suggesting that the stock is 67.831% less volatile than S&P 500. In comparison Moderna has a beta of 2.231, suggesting its more volatile than the S&P 500 by 123.128%.

Gilead Sciences has a quarterly dividend of $0.79 per share corresponding to a yield of 3.01%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Gilead Sciences pays 816.25% of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Gilead Sciences quarterly revenues are $6.7B, which are larger than Moderna quarterly revenues of $956M. Gilead Sciences's net income of $1.3B is higher than Moderna's net income of -$1.1B. Notably, Gilead Sciences's price-to-earnings ratio is 21.72x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Gilead Sciences is 4.53x versus 3.30x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of 19.72% compared to Gilead Sciences's net margin of 31.35%. Gilead Sciences's return on equity of 32.29% beat Vertex Pharmaceuticals's return on equity of -3.23%.

Gilead Sciences has a consensus price target of $113.75, signalling upside risk potential of 10.26%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $500.32 which suggests that it could grow by 1.31%. Given that Gilead Sciences has higher upside potential than Vertex Pharmaceuticals, analysts believe Gilead Sciences is more attractive than Vertex Pharmaceuticals.

Gilead Sciences has a beta of 0.322, which suggesting that the stock is 67.831% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.504, suggesting its less volatile than the S&P 500 by 49.617%.

Gilead Sciences has a quarterly dividend of $0.79 per share corresponding to a yield of 3.01%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Gilead Sciences pays 816.25% of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

Gilead Sciences quarterly revenues are $6.7B, which are larger than Vertex Pharmaceuticals quarterly revenues of $2.9B. Gilead Sciences's net income of $1.3B is higher than Vertex Pharmaceuticals's net income of $913M. Notably, Gilead Sciences's price-to-earnings ratio is 21.72x while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Gilead Sciences is 4.53x versus 11.62x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.